Recent interest has focused on the efficacy of ADCs in treating HER2-low breast cancer, defined as a HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization (ISH). The gene discussed is ERBB2; the disease is breast carcinoma.